Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker
October 17, 2024 03:11 PM EDT
Financing
Startups

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Josh Bilenker and Jeff En­gel­man’s se­cre­tive start­up Tree­line Bio­sciences has an­oth­er $421 mil­lion, ac­cord­ing to a new SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

Mer­ck KGaA eyes more man­u­fac­tur­ing M&A as it faces head­winds in Chi­na

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times